Begin typing your search above and press return to search.
WHO Advises Not To Use Remdesivir Drug To Treat Covid-19 Patients
By: Tupaki Desk | 20 Nov 2020 8:05 AM GMT
As the efforts and clinical trials to treat the ongoing Coronavirus continue, one after the other techniques and medicines which came in handy in tackling the virus started turning out to be not advisable for treatment.
In a much shocking development, specified health agency World Health Organisation (WHO) advised to not use Remdesivir to treat the patients who were hospitalized with Covid-19.
The WHO said there is no adequate evidence to prove that Remdesivir helps in improving the survival rate of the patients who takes the drug and advised them not to use it.
To conclude the advice, the WHO Guideline Development Group (GDG) has reviewed the situation of more than 7,000 patients who were part of the four randomised clinical trials globally.
The Remdesivir which is developed by the pharmaceutical company Gilead Sciences based out of California, United States showed promising results in the trials during the initial days of Covid-19 treatment.
However, the new study emphasized the lack of effectiveness in treating the Coronavirus patients irrespective of the Covid-19 levels.
It has to be noted that, the other day, the apex clinical body in India, the Indian Council of Medical Research(ICMR) said indiscriminate use of Convalescent Plasma Therapy (CPT) should be avoided as the procedure does not bring down the mortality in Covid-19 patients.
Now all the eyes are on the clinical trials of three vaccines, which have reached the third phase.
In a much shocking development, specified health agency World Health Organisation (WHO) advised to not use Remdesivir to treat the patients who were hospitalized with Covid-19.
The WHO said there is no adequate evidence to prove that Remdesivir helps in improving the survival rate of the patients who takes the drug and advised them not to use it.
To conclude the advice, the WHO Guideline Development Group (GDG) has reviewed the situation of more than 7,000 patients who were part of the four randomised clinical trials globally.
The Remdesivir which is developed by the pharmaceutical company Gilead Sciences based out of California, United States showed promising results in the trials during the initial days of Covid-19 treatment.
However, the new study emphasized the lack of effectiveness in treating the Coronavirus patients irrespective of the Covid-19 levels.
It has to be noted that, the other day, the apex clinical body in India, the Indian Council of Medical Research(ICMR) said indiscriminate use of Convalescent Plasma Therapy (CPT) should be avoided as the procedure does not bring down the mortality in Covid-19 patients.
Now all the eyes are on the clinical trials of three vaccines, which have reached the third phase.
